Want to see AVR full AI Analyst Report?
AVR Stock Chart & Stats
$8.13
$0.04(0.49%)
At close: 4:00 PM EDT
$8.13
$0.04(0.49%)
Day’s Range― - ―
52-Week Range$3.30 - $11.06
Previous Close$8.18
Volume838.13K
Average Volume (3M)151.40K
Market Cap
$875.18M
Enterprise Value$705.02
Total Cash (Recent Filing)$257.38M
Total Debt (Recent Filing)$3.32M
Price to Earnings (P/E)―
Beta1.90
Next Earnings
Nov 18, 2026EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.76
Shares Outstanding97,458,470
10 Day Avg. Volume215,658
30 Day Avg. Volume151,395
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)-1.98K
Price to Sales (P/S)96.28
P/FCF Ratio-2.31
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$15.33Price Target Upside88.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.2
Revenue Forecast (FY)$8.88M
Bulls Say, Bears Say
Bulls Say
Revenue And Gross Margin ImprovementImproving revenue and gross margin indicate growing commercial traction and better product economics. If sustained, these trends could provide operating leverage as Anteris advances its heart-valve portfolio and expands beyond its currently small revenue base.
Low Financial LeverageVery low leverage reduces interest burden and refinancing exposure, preserving financial flexibility while the company funds development. The sizable equity base provides a buffer against operating volatility, although future funding needs remain important.
Capital Access For DurAVR DevelopmentFlexible access to equity capital can support continued development and commercialization of the DurAVR Transcatheter Heart Valve System. Sustained funding may help Anteris pursue its structural-heart opportunity without relying solely on debt.
Bears Say
Deep And Expanding Operating LossesThe company remains far from profitability, and operating costs have not scaled with revenue growth. Persistent losses could limit strategic flexibility, increase reliance on external financing, and delay the point at which the business can fund development internally.
Severe Cash BurnDeeply negative operating and free cash flow show that Anteris consumes substantial cash while developing its products. Continued deficits may require repeated capital raises, creating funding dependence and potentially constraining investment if financing conditions weaken.
Equity Dilution And Compliance ExposureThe planned equity program can fund operations but would dilute existing holders if heavily used. Separately, the cleansing-notice lapse highlights regulatory execution risk, with ASIC or other parties retaining a defined period to challenge the court orders.
Anteris Technologies Global Corp. News
AVR FAQ
What was Anteris Technologies Global Corp.’s price range in the past 12 months?
Anteris Technologies Global Corp. lowest stock price was $3.30 and its highest was $11.05 in the past 12 months.
What is Anteris Technologies Global Corp.’s market cap?
Anteris Technologies Global Corp.’s market cap is $875.18M.
When is Anteris Technologies Global Corp.’s upcoming earnings report date?
Anteris Technologies Global Corp.’s upcoming earnings report date is Nov 18, 2026 which is in 86 days.
How were Anteris Technologies Global Corp.’s earnings last quarter?
Anteris Technologies Global Corp. released its earnings results on Aug 11, 2026. The company reported -$0.3 earnings per share for the quarter, missing the consensus estimate of -$0.207 by -$0.093.
Is Anteris Technologies Global Corp. overvalued?
According to Wall Street analysts Anteris Technologies Global Corp.’s price is currently Undervalued.
Does Anteris Technologies Global Corp. pay dividends?
Anteris Technologies Global Corp. does not currently pay dividends.
What is Anteris Technologies Global Corp.’s EPS estimate?
Anteris Technologies Global Corp.’s EPS estimate is -0.31.
How many shares outstanding does Anteris Technologies Global Corp. have?
Anteris Technologies Global Corp. has 97,458,470 shares outstanding.
What happened to Anteris Technologies Global Corp.’s price movement after its last earnings report?
Anteris Technologies Global Corp. reported an EPS of -$0.3 in its last earnings report, missing expectations of -$0.207. Following the earnings report the stock price went down -3.272%.
Which hedge fund is a major shareholder of Anteris Technologies Global Corp.?
Currently, no hedge funds are holding shares in AVR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Anteris Technologies Global Corp. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.33 (88.60% Upside)
$15.33 (88.60% Upside)
Blogger Sentiment
Bearish
AVR Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 602.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $25.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.3%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-14.53%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
583.35%
Trailing 12-Months
Company Description
Anteris Technologies Global Corp.
Anteris Technologies Global Corp. is a structural heart innovator dedicated to discovering, developing, and bringing to market medical devices that enhance the well-being of patients grappling with aortic stenosis. The company's premier offering is the DurAVR transcatheter heart valve system, a pioneering transcatheter aortic valve engineered to treat aortic stenosis by precisely emulating the performance of a healthy human aortic valve. Beyond this, Anteris develops ADAPT anti-calcification tissue, a unique preparation that transforms xenograft tissue into robust bioscaffolds. These bioscaffolds are designed to simulate human tissue for various surgical repairs, notably in aortic valve replacement. Additionally, the ComASUR delivery system, a physician-designed balloon-expandable apparatus, features a reinforced, steerable catheter. This allows for highly accurate navigation through cardiac anatomy in a controlled manner, thereby mitigating potential damage to the aorta. Founded in 1999, Anteris Technologies Global Corp. operates out of Toowong, Australia.
AVR Stock 12 Month Forecast
Average Price Target
$15.33
▲(88.60% Upside)
Technical Analysis
Anika Therapeutics
―
Apyx Medical
―
Inogen
―
Treace Medical Concepts
―
Rapid Micro Biosystems
―
Ownership Overview
5.44% Insiders
6.43% Mutual Funds
38.40% Other Institutional Investors
43.52% Public Companies and
Individual Investors











